One Year Follow-Up of COVID-19 Related Symptoms and Patient Quality of Life: A Prospective Cohort Study
Yonsei Medical Journal 2022³â 63±Ç 6È£ p.499 ~ p.510
±èÀ±Á¤(Kim Yoon-Jung) - Kyungpook National University School of Medicine Department of Internal Medicine
±è½Å¿ì(Kim Shin-Woo) - Kyungpook National University School of Medicine Department of Internal Medicine
ÀåÇöÇÏ(Chang Hyun-Ha) - Kyungpook National University School of Medicine Department of Internal Medicine
±Ç±âÅÂ(Kwon Ki-Tae) - Kyungpook National University School of Medicine Department of Internal Medicine
Ȳ¼ÒÀ±(Hwang So-Yoon) - Kyungpook National University School of Medicine Department of Internal Medicine
¹è¼ÒÇö(Bae So-Hyun) - Kyungpook National University School of Medicine Department of Internal Medicine
Abstract
Purpose: Globally, concerns have grown regarding the long-term effects of novel coronavirus disease (COVID-19) infection. Therefore, we evaluated the long-term course of persistent symptoms and patient quality of life.
Materials and Methods: This prospective cohort study was conducted at a single tertiary university hospital from August 31, 2020 to March 29, 2021 with adult patients followed at 6 and 12 months after acute COVID-19 symptom onset or diagnosis. Clinical characteristics, self-reported symptoms, EuroQol 5 dimension 5 level (EQ5D-5L) index scores, Korean version of the Patient Health Questionnaire-9 (PHQ-9), Korean version of the Posttraumatic Stress Disorder Checklist-5 (PCL-5-K), and Generalized Anxiety Disorder-7 (GAD-7) were investigated. Symptom persistent or non-persistent groups were defined according to persistency of COVID-19 related symptoms or signs after acute COVID-19 infection, respectively.
Results: Of all 235 patients, 170 (64.6%) patients were eligible for analysis. The median age was 51 (interquartile range, 37?61) years old, and 102 patients were female (60.0%). After 12 months from acute COVID-19 infection, in total, 83 (48.8%) patients still suffered from COVID-19-related symptoms. The most common symptoms included amnesia (24.1%), insomnia (14.7%), fatigue (13.5%), and anxiety (12.9%). Among the five EQ5D-5L categories, the average value of anxiety or depression was the most predominant. PHQ-9 and PCL-5-K scores were statistically higher in the COVID-19?related symptom persistent group than the non-persistent group (p=0.001). However, GAD-7 scores showed no statistical differences between the two groups (p=0.051).
Conclusion: Neuropsychiatric symptoms were the major COVID-19?related symptoms after 12 months from acute COVID-19 infection, reducing quality of life.
Å°¿öµå
COVID-19, SARS-CoV-2, persistent symptoms, long-term consequences, long COVID, life quality, health-related quality of life
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The most frequently identified symptoms at 12 months after acute COVID-19 infection involved amnesia in 41 (24.1%) patients, insomnia in 25 (14.7%) patients, fatigue in 23 (13.5%) patients, anxiety in 22 (12.9%) patients, and arthralgia in 20 (11.8%) patients.